2.20
price down icon7.56%   -0.18
pre-market  Pre-market:  2.27   0.07   +3.18%
loading
Macrogenics Inc stock is traded at $2.20, with a volume of 341.49K. It is down -7.56% in the last 24 hours and down -10.57% over the past month. Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
See More
Previous Close:
$2.38
Open:
$2.39
24h Volume:
341.49K
Relative Volume:
0.60
Market Cap:
$138.08M
Revenue:
$139.77M
Net Income/Loss:
$-97.62M
P/E Ratio:
-1.3924
EPS:
-1.58
Net Cash Flow:
$-61.71M
1W Performance:
-9.09%
1M Performance:
-10.57%
6M Performance:
-40.54%
1Y Performance:
-86.71%
1-Day Range:
Value
$2.17
$2.415
1-Week Range:
Value
$2.16
$2.485
52-Week Range:
Value
$2.16
$19.54

Macrogenics Inc Stock (MGNX) Company Profile

Name
Name
Macrogenics Inc
Name
Phone
301-251-5172
Name
Address
9704 MEDICAL CENTER DRIVE, Rockville, MD
Name
Employee
339
Name
Twitter
@macrogenics
Name
Next Earnings Date
2025-03-07
Name
Latest SEC Filings
Name
MGNX's Discussions on Twitter

Compare MGNX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
MGNX
Macrogenics Inc
2.20 138.08M 139.77M -97.62M -61.71M -1.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.92 129.14B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.61 74.41B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.21 35.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.75 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.57 27.35B 3.32B -860.46M -1.04B -8.32

Macrogenics Inc Stock (MGNX) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-07-24 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Aug-01-24 Downgrade BTIG Research Buy → Neutral
Jul-31-24 Downgrade B. Riley Securities Buy → Neutral
Jul-31-24 Downgrade Guggenheim Buy → Neutral
May-10-24 Downgrade BMO Capital Markets Outperform → Market Perform
May-10-24 Downgrade Stifel Buy → Hold
May-10-24 Downgrade TD Cowen Buy → Hold
Apr-26-24 Initiated B. Riley Securities Buy
Apr-09-24 Upgrade TD Cowen Hold → Buy
Mar-04-24 Reiterated BTIG Research Buy
Feb-14-24 Downgrade H.C. Wainwright Buy → Neutral
Dec-20-23 Upgrade Citigroup Neutral → Buy
Nov-07-23 Upgrade Guggenheim Neutral → Buy
Mar-17-23 Downgrade Guggenheim Buy → Neutral
Nov-22-22 Downgrade Cowen Outperform → Market Perform
Nov-14-22 Upgrade BMO Capital Markets Market Perform → Outperform
Jul-18-22 Downgrade SMBC Nikko Outperform → Neutral
Jul-11-22 Downgrade BMO Capital Markets Outperform → Market Perform
May-04-22 Downgrade Guggenheim Buy → Neutral
Feb-28-22 Upgrade Citigroup Neutral → Buy
Feb-11-22 Initiated BMO Capital Markets Outperform
Feb-04-22 Initiated SMBC Nikko Outperform
Nov-17-21 Resumed Guggenheim Buy
Oct-19-21 Initiated JMP Securities Mkt Outperform
Oct-15-21 Resumed BTIG Research Buy
Apr-26-21 Resumed Credit Suisse Outperform
Mar-12-21 Upgrade Barclays Underweight → Overweight
Dec-22-20 Resumed H.C. Wainwright Buy
Aug-03-20 Downgrade Citigroup Buy → Neutral
Jun-01-20 Upgrade Guggenheim Neutral → Buy
May-26-20 Reiterated H.C. Wainwright Buy
Mar-04-20 Initiated Barclays Underweight
Dec-19-19 Initiated Cantor Fitzgerald Overweight
Dec-18-19 Initiated Cantor Fitzgerald Overweight
Nov-21-19 Downgrade Morgan Stanley Equal-Weight → Underweight
Nov-20-19 Resumed Guggenheim Neutral
May-03-19 Upgrade Wedbush Neutral → Outperform
Apr-12-19 Initiated Guggenheim Neutral
Feb-07-19 Upgrade Citigroup Sell → Buy
Feb-07-19 Downgrade Wedbush Outperform → Neutral
Feb-06-19 Upgrade Raymond James Underperform → Mkt Perform
Feb-04-19 Downgrade Citigroup Neutral → Sell
Dec-10-18 Downgrade Raymond James Outperform → Underperform
Sep-10-18 Resumed BTIG Research Buy
May-31-18 Initiated Evercore ISI Outperform
Mar-05-18 Initiated H.C. Wainwright Buy
Mar-31-17 Initiated Raymond James Outperform
View All

Macrogenics Inc Stock (MGNX) Latest News

pulisher
Mar 13, 2025

MacroGenics (MGNX) to Release Quarterly Earnings on Thursday - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

MGNX LAWSUIT ALERT: Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire

Mar 12, 2025
pulisher
Mar 12, 2025

MacroGenics at Barclays Conference: Strategic Insights on Pipeline and Partnerships - Investing.com

Mar 12, 2025
pulisher
Mar 12, 2025

MGNX Deadline: MGNX Investors with Losses in Excess of $100K Hav - GuruFocus.com

Mar 12, 2025
pulisher
Mar 11, 2025

MacroGenics at Leerink’s Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada

Mar 11, 2025
pulisher
Mar 09, 2025

MacroGenics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before September 24, 2024 to Discuss Your RightsMGNX - ACCESS Newswire

Mar 09, 2025
pulisher
Mar 06, 2025

Levi & Korsinsky Notifies Shareholders of MacroGenics, Inc. (MGNX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Mar 06, 2025
pulisher
Mar 06, 2025

MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call - GlobeNewswire

Mar 06, 2025
pulisher
Mar 06, 2025

MacroGenics at TD Cowen Conference: Strategic Innovations in Immunotherapy - Investing.com India

Mar 06, 2025
pulisher
Mar 06, 2025

MacroGenics, Inc. to Announce 2024 Financial Results on March 20, 2025 - Nasdaq

Mar 06, 2025
pulisher
Mar 06, 2025

MacroGenics Earnings: Will Q4 Results Reveal Biotech's Growth Trajectory? - StockTitan

Mar 06, 2025
pulisher
Mar 06, 2025

MacroGenics Inc earnings beat by $0.33, revenue topped estimates - Investing.com Australia

Mar 06, 2025
pulisher
Mar 06, 2025

MacroGenics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 06, 2025
pulisher
Mar 05, 2025

Three Companies Surpass Quarterly Earnings Expectations - Evrim Ağacı

Mar 05, 2025
pulisher
Mar 05, 2025

Long-Term Investors in shares of MacroGenics, Inc. (NASDAQ: - openPR

Mar 05, 2025
pulisher
Mar 05, 2025

Investors Who Lost Money on MacroGenics, Inc. (MGNX) Should Contact Levi & Korsinsky About Pending Class ActionMGNX - ACCESS Newswire

Mar 05, 2025
pulisher
Mar 04, 2025

Macrogenics Stock Hits 52-Week Low at $2.31 Amid Sharp Decline - Investing.com India

Mar 04, 2025
pulisher
Mar 03, 2025

MacroGenics, Inc. Class Action: Levi & Korsinsky Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024MGNX - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

Macrogenics Stock Hits 52-Week Low at $2.31 Amid Sharp Decline By Investing.com - Investing.com South Africa

Mar 03, 2025
pulisher
Mar 03, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics, Inc. LawsuitMGNX - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 02, 2025

Levi & Korsinsky Reminds MacroGenics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsMGNX - ACCESS Newswire

Mar 02, 2025
pulisher
Mar 02, 2025

MACROGENICS Earnings Preview: Recent $MGNX Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 02, 2025
pulisher
Mar 01, 2025

Levi & Korsinsky Reminds MacroGenics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024MGNX - ACCESS Newswire

Mar 01, 2025
pulisher
Mar 01, 2025

MacroGenics, Inc. (MGNX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire

Mar 01, 2025
pulisher
Feb 28, 2025

Shareholders that lost money on MacroGenics, Inc. (MGNX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 28, 2025

Sept. 24th Deadline Alert: Investors Who Lost More Than $100,000 With MacroGenics, Inc. (NASDAQ:MGNX) Shares Should Contact the Shareholders Foundation - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 28, 2025

MacroGenics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by MacroGenics, Inc. (MGNX) - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 28, 2025

MacroGenics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud AllegationsMGNX - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 28, 2025

Shareholder Rights Advocates at Levi & Korsinsky Investigate MacroGenics, Inc. (MGNX) Regarding Possible Securities Fraud Violations - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 28, 2025

MacroGenics, Inc. (NASDAQ:MGNX) Not Doing Enough For Some Investors As Its Shares Slump 26% - Simply Wall St

Feb 28, 2025
pulisher
Feb 28, 2025

Lost Money on MacroGenics, Inc. (MGNX)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 27, 2025

Levi & Korsinsky Reminds Shareholders of an Investigation into MacroGenics, Inc. (MGNX) Regarding Potential Securities Fraud Allegations - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMGNX - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

MacroGenics: Stacking Up A Lot Of Headwinds... But It's Fallen Too Far - Seeking Alpha

Feb 27, 2025
pulisher
Feb 27, 2025

MacroGenics to Participate in Upcoming Investor Conferences - GlobeNewswire

Feb 27, 2025
pulisher
Feb 27, 2025

How Will MacroGenics Address Investors at Three Key Healthcare Conferences? - StockTitan

Feb 27, 2025
pulisher
Feb 27, 2025

MacroGenics (MGNX) to Release Earnings on Thursday - Defense World

Feb 27, 2025
pulisher
Feb 27, 2025

MacroGenics CEO departure date extended amid search for successor By Investing.com - Investing.com Australia

Feb 27, 2025
pulisher
Feb 26, 2025

Shareholders of MacroGenics, Inc. Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights – MGNX - ACCESS Newswire

Feb 26, 2025
pulisher
Feb 26, 2025

MacroGenics CEO departure date extended amid search for successor - Investing.com

Feb 26, 2025
pulisher
Feb 26, 2025

MacroGenics Extends CEO’s Separation Agreement - TipRanks

Feb 26, 2025
pulisher
Feb 25, 2025

MGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of MacroGenics, Inc. to Contact the Firm Today! - ACCESS Newswire

Feb 25, 2025
pulisher
Feb 23, 2025

Levi & Korsinsky Notifies Shareholders of MacroGenics, Inc.(MGNX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Feb 23, 2025
pulisher
Feb 23, 2025

Shareholders that lost money on MacroGenics, Inc.(MGNX) should contact Levi & Korsinsky about pending Class ActionMGNX - ACCESS Newswire

Feb 23, 2025
pulisher
Feb 23, 2025

Shareholders that Lost Money on MacroGenics, Inc. (MGNX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire

Feb 23, 2025
pulisher
Feb 22, 2025

MGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MacroGenics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Feb 22, 2025
pulisher
Feb 22, 2025

Investor Network: MacroGenics, Inc. to Host Earnings Call - ACCESS Newswire

Feb 22, 2025
pulisher
Feb 22, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics LawsuitMGNX - ACCESS Newswire

Feb 22, 2025
pulisher
Feb 20, 2025

MacroGenics, Inc. Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for DetailsMGNX - ACCESS Newswire

Feb 20, 2025
pulisher
Feb 20, 2025

Macrogenics VP Beth Smith sells $1,082 in common stock - Investing.com India

Feb 20, 2025
pulisher
Feb 19, 2025

Macrogenics VP Beth Smith sells $1,082 in common stock By Investing.com - Investing.com South Africa

Feb 19, 2025

Macrogenics Inc Stock (MGNX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
Cap:     |  Volume (24h):